Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 390

1.

An unexpected manifestation of gout.

Gamala M, Jacobs JWG, Heggelman BGF, Klaasen R.

Rheumatology (Oxford). 2019 Sep 24. pii: kez426. doi: 10.1093/rheumatology/kez426. [Epub ahead of print] No abstract available.

PMID:
31549169
2.

The performance of dual-energy CT in the classification criteria of gout: a prospective study in subjects with unclassified arthritis.

Gamala M, Jacobs JWG, Linn-Rasker SF, Nix M, Heggelman BGF, Pasker-de Jong PCM, van Laar JM, Klaasen R.

Rheumatology (Oxford). 2019 Sep 5. pii: kez391. doi: 10.1093/rheumatology/kez391. [Epub ahead of print]

PMID:
31504985
3.

Gout and hyperuricaemia: a worldwide health issue of joints and beyond.

Gamala M, Jacobs JWG.

Rheumatology (Oxford). 2019 Jul 11. pii: kez272. doi: 10.1093/rheumatology/kez272. [Epub ahead of print] No abstract available.

PMID:
31298293
4.

Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials.

Verhoeven MM, de Hair MJ, Tekstra J, Bijlsma JW, van Laar JM, Pethoe-Schramm A, Borm ME, Ter Borg EJ, Linn-Rasker SP, Teitsma XM, Lafeber FP, Jacobs JW, Welsing PM.

Ann Rheum Dis. 2019 Oct;78(10):1333-1338. doi: 10.1136/annrheumdis-2019-215304. Epub 2019 Jun 13.

PMID:
31196844
5.

The diagnostic performance of dual energy CT for diagnosing gout: a systematic literature review and meta-analysis.

Gamala M, Jacobs JWG, van Laar JM.

Rheumatology (Oxford). 2019 May 14. pii: kez180. doi: 10.1093/rheumatology/kez180. [Epub ahead of print]

PMID:
31089688
6.

Effectiveness of Remission Induction Strategies for Early Rheumatoid Arthritis: a Systematic Literature Review.

Verhoeven MMA, Welsing PMJ, Bijlsma JWJ, van Laar JM, Lafeber FPJG, Tekstra J, Jacobs JWG.

Curr Rheumatol Rep. 2019 Apr 23;21(6):24. doi: 10.1007/s11926-019-0821-1. Review.

7.

Novel optical spectral transmission (OST)-guided versus conventionally disease activity-guided treatment: study protocol of a randomized clinical trial on guidance of a treat-to-target strategy for early rheumatoid arthritis.

Besselink NJ, Westgeest AAA, Klaasen R, Gamala M, van Woerkom JM, Tekstra J, Verhoeven MMA, Van Spil WE, Lafeber FPJG, Marijnissen ACA, Van Laar JM, Jacobs JWG.

Trials. 2019 Apr 17;20(1):226. doi: 10.1186/s13063-019-3285-8.

8.

Is prediction of clinical response to methotrexate in individual rheumatoid arthritis patients possible? A systematic literature review.

Roodenrijs NMT, van der Goes MC, Welsing PMJ, Tekstra J, van Laar JM, Lafeber FPJG, Bijlsma JWJ, Jacobs JWG.

Joint Bone Spine. 2019 Apr 11. pii: S1297-319X(19)30054-5. doi: 10.1016/j.jbspin.2019.04.002. [Epub ahead of print]

PMID:
30981868
9.

Can optical spectral transmission assess ultrasound-detected synovitis in hand osteoarthritis?

Besselink NJ, Jacobs JWG, Westgeest AAA, van der Meijde P, Welsing PMJ, Marijnissen ACA, Lafeber FPJG, Van Spil WE.

PLoS One. 2019 Feb 22;14(2):e0209761. doi: 10.1371/journal.pone.0209761. eCollection 2019.

10.

Limits of traditional evidence-based medicine methodologies exemplified by the novel era in psoriatic arthritis drug development.

Leijten EF, Radstake TR, McInnes IB, Jacobs JW.

Expert Rev Clin Immunol. 2019 May;15(5):441-444. doi: 10.1080/1744666X.2019.1580144. Epub 2019 Feb 18. No abstract available.

PMID:
30729823
11.

Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice.

Finn PD, Rodriguez D, Kohler J, Jiang Z, Wan S, Blanco E, King AJ, Chen T, Bell N, Dragoli D, Jacobs JW, Jain R, Leadbetter M, Siegel M, Carreras CW, Koo-McCoy S, Shaw K, Le C, Vanegas S, Hsu IH, Kozuka K, Okamoto K, Caldwell JS, Lewis JG.

Am J Physiol Gastrointest Liver Physiol. 2019 Mar 1;316(3):G412-G424. doi: 10.1152/ajpgi.00300.2018. Epub 2019 Jan 3.

12.

Adalimumab drug and antidrug antibody levels do not predict flare risk after stopping adalimumab in RA patients with low disease activity.

Lamers-Karnebeek FBG, Jacobs JWG, Radstake TRDJ, van Riel PLCM, Jansen TL.

Rheumatology (Oxford). 2019 Mar 1;58(3):427-431. doi: 10.1093/rheumatology/key292.

PMID:
30383251
13.

Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology.

Teitsma XM, Yang W, Jacobs JWG, Pethö-Schramm A, Borm MEA, Harms AC, Hankemeier T, van Laar JM, Bijlsma JWJ, Lafeber FPJG.

Arthritis Res Ther. 2018 Oct 15;20(1):230. doi: 10.1186/s13075-018-1729-2.

14.

Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey.

Roodenrijs NMT, de Hair MJH, van der Goes MC, Jacobs JWG, Welsing PMJ, van der Heijde D, Aletaha D, Dougados M, Hyrich KL, McInnes IB, Mueller-Ladner U, Senolt L, Szekanecz Z, van Laar JM, Nagy G; whole EULAR Task Force on development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis.

Ann Rheum Dis. 2018 Dec;77(12):1705-1709. doi: 10.1136/annrheumdis-2018-213687. Epub 2018 Sep 7.

PMID:
30194273
15.

Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis.

Teitsma XM, Jacobs JWG, de Jong PHP, Hazes JMW, Weel AEAM, Welsing PMJ, Pethö-Schramm A, Borm MEA, van Laar JM, Bijlsma JWJ, Lafeber FPJG.

Ann Rheum Dis. 2019 Jan;78(1):142-144. doi: 10.1136/annrheumdis-2018-213767. Epub 2018 Aug 29. No abstract available.

PMID:
30158123
16.

Design of Gut-Restricted Thiazolidine Agonists of G Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5).

Chen T, Reich NW, Bell N, Finn PD, Rodriguez D, Kohler J, Kozuka K, He L, Spencer AG, Charmot D, Navre M, Carreras CW, Koo-McCoy S, Tabora J, Caldwell JS, Jacobs JW, Lewis JG.

J Med Chem. 2018 Sep 13;61(17):7589-7613. doi: 10.1021/acs.jmedchem.8b00308. Epub 2018 Aug 24.

PMID:
30141927
17.

Dual target strategy: a proposal to mitigate the risk of overtreatment and enhance patient satisfaction in rheumatoid arthritis.

Ferreira RJO, Ndosi M, de Wit M, Santos EJF, Duarte C, Jacobs JWG, Machado PM, van der Heijde D, Gossec L, da Silva JAP.

Ann Rheum Dis. 2019 Oct;78(10):e109. doi: 10.1136/annrheumdis-2018-214199. Epub 2018 Aug 20. No abstract available.

PMID:
30127056
18.

Correspondence to viewpoint 'Defining refractory rheumatoid arthritis' by Buch.

Roodenrijs NM, de Hair MJ, van der Goes MC, Jacobs JW.

Ann Rheum Dis. 2019 Oct;78(10):e105. doi: 10.1136/annrheumdis-2018-214147. Epub 2018 Jul 30. No abstract available.

PMID:
30061163
19.

Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors.

Teitsma XM, Jacobs JWG, Welsing PMJ, de Jong PHP, Hazes JMW, Weel AEAM, Pethö-Schramm A, Borm MEA, van Laar JM, Lafeber FPJG, Bijlsma JWJ.

Ann Rheum Dis. 2018 Sep;77(9):1261-1267. doi: 10.1136/annrheumdis-2018-213035. Epub 2018 May 14.

PMID:
29760159
20.

Explorative analyses of protein biomarkers in patients with early rheumatoid arthritis achieving sustained drug-free remission after treatment with tocilizumab- or methotrexate-based strategies: from transcriptomics to proteomics.

Teitsma XM, Jacobs JWG, Concepcion AN, Pethö-Schramm A, Borm MEA, van Laar JM, Bijlsma JWJ, Lafeber FPJG.

Clin Exp Rheumatol. 2018 Nov-Dec;36(6):976-983. Epub 2018 May 8.

21.

An Evaluation of the Pharmacodynamics, Safety, and Tolerability of the Potassium Binder RDX7675.

Pitt B, Zann V, Roe C, Jacobs JW, Davidson JP, Dowd C, Kumaraswamy P, Lin F, Korner P, Blanks RC, Rosenbaum DP.

J Clin Pharmacol. 2018 Apr 12. doi: 10.1002/jcph.1102. [Epub ahead of print]

PMID:
29645278
22.

The impact of patient global assessment in the definition of remission as a predictor of long-term radiographic damage in patients with rheumatoid arthritis: protocol for an individual patient data meta-analysis.

Ferreira RJO, Welsing PMJ, Gossec L, Jacobs JWG, Machado PM, Ndosi M, van der Heijde D, da Silva JAP.

Acta Reumatol Port. 2018 Jan-Mar;43(1):52-60.

23.

Glucocorticoids Are Always Under Suspicion - Is the Perception of Their Risks Unbiased?

Jacobs JWG, Pereira DA Silva JA.

J Rheumatol. 2018 Mar;45(3):293-296. doi: 10.3899/jrheum.171331. No abstract available.

PMID:
29496913
24.

Optical spectral transmission to assess inflammation in hand and wrist joints of rheumatoid arthritis patients.

Besselink NJ, van der Meijde P, Rensen WHJ, Meijer PBL, Marijnissen ACA, van Laar JM, Lafeber FPJG, Jacobs JWG.

Rheumatology (Oxford). 2018 May 1;57(5):865-872. doi: 10.1093/rheumatology/kex531.

PMID:
29471516
25.

Can baseline ultrasound results help to predict failure to achieve DAS28 remission after 1 year of tight control treatment in early RA patients?

Ten Cate DF, Jacobs JWG, Swen WAA, Hazes JMW, de Jager MH, Basoski NM, Haagsma CJ, Luime JJ, Gerards AH.

Arthritis Res Ther. 2018 Jan 30;20(1):15. doi: 10.1186/s13075-018-1514-2.

26.

Gouty arthritis: decision-making following dual-energy CT scan in clinical practice, a retrospective analysis.

Gamala M, Linn-Rasker SP, Nix M, Heggelman BGF, van Laar JM, Pasker-de Jong PCM, Jacobs JWG, Klaasen R.

Clin Rheumatol. 2018 Jul;37(7):1879-1884. doi: 10.1007/s10067-018-3980-y. Epub 2018 Jan 27.

27.
28.

Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers.

Rosenbaum DP, Yan A, Jacobs JW.

Clin Drug Investig. 2018 Apr;38(4):341-351. doi: 10.1007/s40261-017-0614-0.

29.

Efficacy and safety of selective glucocorticoid receptor modulators in comparison to glucocorticoids in arthritis, a systematic review.

Safy M, de Hair MJH, Jacobs JWG, Buttgereit F, Kraan MC, van Laar JM.

PLoS One. 2017 Dec 21;12(12):e0188810. doi: 10.1371/journal.pone.0188810. eCollection 2017. Review.

30.

Evaluation of the Pharmacodynamic Effects of the Potassium Binder RDX7675 in Mice.

Davidson JP, King AJ, Kumaraswamy P, Caldwell JS, Korner P, Blanks RC, Jacobs JW.

J Cardiovasc Pharmacol Ther. 2018 May;23(3):244-253. doi: 10.1177/1074248417741685. Epub 2017 Nov 12.

31.

Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies.

Teitsma XM, Jacobs JWG, Welsing PMJ, Pethö-Schramm A, Borm MEA, van Laar JM, Lafeber FPJG, Bijlsma JWJ.

Rheumatology (Oxford). 2018 Feb 1;57(2):309-317. doi: 10.1093/rheumatology/kex386.

PMID:
29095992
32.

Chronic widespread pain and increased mortality: biopsychosocial interconnections.

Da Silva JAP, Geenen R, Jacobs JWG.

Ann Rheum Dis. 2018 Jun;77(6):790-792. doi: 10.1136/annrheumdis-2017-211893. Epub 2017 Oct 22. No abstract available.

PMID:
29056587
33.

Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need.

de Hair MJH, Jacobs JWG, Schoneveld JLM, van Laar JM.

Rheumatology (Oxford). 2017 Oct 4. doi: 10.1093/rheumatology/kex349. [Epub ahead of print]

PMID:
29029308
34.

Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy.

Teitsma XM, Jacobs JWG, Welsing PMJ, Pethö-Schramm A, Borm MEA, Hendriks L, Denissen NHAM, van Laar JM, Lafeber FPJG, Bijlsma JWJ.

Rheumatology (Oxford). 2017 Dec 1;56(12):2179-2189. doi: 10.1093/rheumatology/kex319.

PMID:
29029185
35.

Do we need bone mineral density to estimate osteoporotic fracture risk? A 10-year prospective multicentre validation study.

Marques A, Lucas R, Simões E, Verstappen SMM, Jacobs JWG, da Silva JAP.

RMD Open. 2017 Sep 26;3(2):e000509. doi: 10.1136/rmdopen-2017-000509. eCollection 2017.

36.

Response to eLetter: 'Discussion of methotrexate dosage' by Maguire et al.

Safy M, Jacobs JWG, Ijff ND, Bijlsma JWJ, van Laar JM, de Hair MJH; Society for Rheumatology Research Utrecht (SRU).

Ann Rheum Dis. 2018 Aug;77(8):e48. doi: 10.1136/annrheumdis-2017-212380. Epub 2017 Oct 9. No abstract available.

PMID:
28993345
37.

Palatability and physical properties of potassium-binding resin RDX7675: comparison with sodium polystyrene sulfonate.

Zann V, McDermott J, Jacobs JW, Davidson JP, Lin F, Korner P, Blanks RC, Rosenbaum DP.

Drug Des Devel Ther. 2017 Sep 6;11:2663-2673. doi: 10.2147/DDDT.S143461. eCollection 2017.

38.

Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy.

Teitsma XM, Jacobs JWG, Mokry M, Borm MEA, Pethö-Schramm A, van Laar JM, Bijlsma JWJ, Lafeber FPJ.

Arthritis Res Ther. 2017 Jul 20;19(1):170. doi: 10.1186/s13075-017-1378-x.

39.

A disconnect between disease activity and functional ability already in patients with early rheumatoid arthritis, depending on large joint involvement.

Rubbert-Roth A, Jacobs JWG, Bijlsma JWJ, Welsing PMJ.

Ann Rheum Dis. 2018 Jul;77(7):1085-1086. doi: 10.1136/annrheumdis-2017-211485. Epub 2017 Jun 23. No abstract available.

PMID:
28646081
40.

Limited value for ultrasonography in predicting flare in rheumatoid arthritis patients with low disease activity stopping TNF inhibitors.

Lamers-Karnebeek FB, Luime JJ, Ten Cate DF, Teerenstra S, Swen NWAA, Gerards AH, Hendrikx J, van Rooyen EM, Voorneman R, Haagsma C, Basoski N, de Jager M, Ghiti Moghadam M, Efde MN, Goekoop-Ruiterman YPM, van Riel PLCM, Jacobs JWG, Jansen TL.

Rheumatology (Oxford). 2017 Sep 1;56(9):1560-1565. doi: 10.1093/rheumatology/kex184.

PMID:
28595367
41.

Can health care providers recognise a fibromyalgia personality?

Da Silva JAP, Jacobs JWG, Branco JC, Canaipa R, Gaspar MF, Griep EN, van Helmond T, Oliveira PJ, Zijlstra TJ, Geenen R.

Clin Exp Rheumatol. 2017 May-Jun;35 Suppl 105(3):43-49. Epub 2017 Feb 23.

42.

Quantifying cutaneous adverse effects of systemic glucocorticoids in patients with rheumatoid arthritis: a cross-sectional cohort study.

Amann J, Wessels AM, Breitenfeldt F, Huscher D, Bijlsma JWJ, Jacobs JWG, Buttgereit F.

Clin Exp Rheumatol. 2017 May-Jun;35(3):471-476. Epub 2017 Jan 15.

PMID:
28094753
43.

Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis.

Strehl C, van der Goes MC, Bijlsma JW, Jacobs JW, Buttgereit F.

Expert Opin Investig Drugs. 2017 Feb;26(2):187-195. doi: 10.1080/13543784.2017.1276562. Epub 2017 Jan 3. Review.

PMID:
28043173
44.

The Computer Assisted Management in Early Rheumatoid Arthritis programme tool used in the CAMERA-I and CAMERA-II studies.

Jacobs JW; Utrecht Rheumatoid Arthritis Cohort study group.

Clin Exp Rheumatol. 2016 Sep-Oct;34(5 Suppl 101):S69-S72. Epub 2016 Oct 18. Review.

45.

Automated joint space width quantification of hand and wrist joints: a proof of concept study.

Huo Y, Veldhuizen RD, van der Heijde DM, Besselink NJ, Jacobs JW, van Laar JM, Viergever MA, Vincken KL, Lafeber FP, de Hair MJ; Society for Rheumatology Research Utrecht investigators.

Clin Exp Rheumatol. 2016 Sep-Oct;34(5 Suppl 101):S34-S39. Epub 2016 Oct 18.

46.

Can adverse effects of glucocorticoid therapy be prevented and treated?

van der Goes MC, Strehl C, Buttgereit F, Bijlsma JW, Jacobs JW.

Expert Opin Pharmacother. 2016 Nov;17(16):2129-2133. Epub 2016 Sep 20. No abstract available.

PMID:
27590884
47.

Necessity of TNF-alpha inhibitor discontinuation in rheumatoid arthritis is predicted by smoking and number of previously used biological DMARDs.

Cuppen BV, Jacobs JW, Ter Borg EJ, Marijnissen AC, Bijlsma JW, Lafeber FP, van Laar JM; all SRU investigators.

Clin Exp Rheumatol. 2017 Mar-Apr;35(2):221-228. Epub 2016 Oct 7.

48.
49.

Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.

Bijlsma JWJ, Welsing PMJ, Woodworth TG, Middelink LM, Pethö-Schramm A, Bernasconi C, Borm MEA, Wortel CH, Ter Borg EJ, Jahangier ZN, van der Laan WH, Bruyn GAW, Baudoin P, Wijngaarden S, Vos PAJM, Bos R, Starmans MJF, Griep EN, Griep-Wentink JRM, Allaart CF, Heurkens AHM, Teitsma XM, Tekstra J, Marijnissen ACA, Lafeber FPJ, Jacobs JWG.

Lancet. 2016 Jul 23;388(10042):343-355. doi: 10.1016/S0140-6736(16)30363-4. Epub 2016 Jun 7.

PMID:
27287832
50.

Determining the Lowest Optimally Effective Methotrexate Dose for Individual RA Patients Using Their Dose Response Relation in a Tight Control Treatment Approach.

Nair SC, Jacobs JW, Bakker MF, Jahangier ZN, Bijlsma JW, van Laar JM, Lafeber FP, Welsing PM; Utrecht Arthritis Cohort Study Group.

PLoS One. 2016 Mar 17;11(3):e0148791. doi: 10.1371/journal.pone.0148791. eCollection 2016.

Supplemental Content

Loading ...
Support Center